Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01362621 · ClinicalTrials.gov registry record
Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 474
- Enrollment target
NCT01362621: Completed study, sponsored by Novartis Pharmaceuticals.
NCT01362621 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 474 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01362621 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 474 participants
- Enrollment target
Study Summary
The study was designed to collect data about inadequately controlled moderate to severe allergic asthma in subjects 6 to \< 12 years of age, managed in a real-world setting.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2008-02 |
What the finished NCT01362621 record still lists
NCT01362621 is an observational study that tracks outcomes without assigning an intervention. The registered 474 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01362621 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01362621 about?
NCT01362621 is a clinical study titled "Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma". The study was designed to collect data about inadequately controlled moderate to severe allergic asthma in subjects 6 to \< 12 years of age, managed in a real-world setting.
What is the current status of trial NCT01362621?
This trial is currently completed. The enrollment target is 474 participants. The study started on 2008-02.
Who is sponsoring clinical trial NCT01362621?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05624996 · 474 participants · Phase 3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- NCT06051695 · 474 participants · Phase 1
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- NCT06632977 · 474 participants · Phase 2
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- NCT01788839 · 475 participants
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia